Arkolith/Insider Trading/MBX/Form 4

Hawryluk P. Kent

President & CEO, DirectorMBX Biosciences, Inc. (MBX) · full profile →Form 4 · filed Mar 16, 2026
Net Buying
Open-Market Buys
$526K
Open-Market Sells
$0
Net Open-Market Flow
$526K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 13, 2026Buy(P)19K$28.41$526K487K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-107268) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML